{"id":"W3134803739","doi":"10.1200/jco.2021.39.6_suppl.327","title":"Outcomes for patients in the pembrolizumab+axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Axitinib; Pembrolizumab; Sunitinib; Renal cell carcinoma; Internal medicine; Clinical endpoint; Population; Oncology; Surgery; Clinical trial; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001346898,0.0006474711,0.001113694,0.0002601614,0.0004359325,0.0007915093,0.000429287,0.0008194998,0.002209348],"category_scores_gemma":[0.000903041,0.0003658483,0.002079292,0.0004259059,0.0002512773,0.0006403512,0.0004888962,0.00116627,0.0003834279],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005552883,"about_ca_system_score_gemma":0.0007000256,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000921273,"about_ca_topic_score_gemma":0.001829525,"domain_scores_codex":[0.9995793,0.0001414395,0.00003662441,0.0001046318,0.00004654561,0.00009150521],"domain_scores_gemma":[0.9993702,0.00007156951,0.0001889901,0.00005783722,0.00003790967,0.0002735819],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5330936,0.005283639,0.4172628,0.0009833188,0.006217552,0.0007869896,0.0002876264,0.001987012,0.007748562,0.0002663539,0.005977103,0.02010541],"study_design_scores_gemma":[0.1342029,0.09605698,0.7523822,0.0001864073,0.004472074,0.001368238,0.0003804668,0.00281451,0.001817138,0.0005071848,0.005716783,0.00009522581],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9954277,0.001032719,0.000169657,0.000114913,0.0000447111,0.0003254519,0.002121257,0.00001212354,0.0007514064],"genre_scores_gemma":[0.9922363,0.0003438545,0.0002342526,0.0003544122,0.00008657145,0.0004859593,0.005323507,0.000005810223,0.0009292598],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002209348,"threshold_uncertainty_score":0.007390976,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1007299146361337,"score_gpt":0.4613804455335913,"score_spread":0.3606505308974576,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}